Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Current Size And Growth Outlook For The Idiopathic Pulmonary Fibrosis Market?

The market size of idiopathic pulmonary fibrosis has experienced robust growth in the past years. It’s expected to expand from $4.15 billion in 2024 to $4.37 billion in 2025, with a compound annual growth rate (CAGR) of 5.2%. The growth during the historic period was driven by factors such as a rise in the aging population, scarcity of treatment options, growing awareness of the disease, and advancements in healthcare infrastructure.

Anticipated robust expansion is envisioned for the idiopathic pulmonary fibrosis market in the upcoming years. The market is projected to escalate to $5.72 billion by 2029, with a compound annual growth rate (CAGR) of 6.9%. The growth during the predicted period can be ascribed to broadened research and development, an approach towards precision medicine, a rising prevalence of the disease, progress in biomarker development, as well as government backing and initiatives. The forecast period is also likely to observe notable trends such as advancements in diagnostic procedures, the onset of targeted treatments, the advent of telemedicine and remote monitoring, combination therapies, and progress in lung transplantation.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12579&type=smp

What Core Drivers Are Expected To Influence The Idiopathic Pulmonary Fibrosis Market?

The idiopathic pulmonary fibrosis market is forecasted to grow, driven primarily by the increasing occurrences of fibrotic illnesses. These conditions, commonly known as fibrosis, are defined by the abnormal production and buildup of fibrous connective tissue in several organs and tissues throughout the human body. Drugs used for idiopathic pulmonary fibrosis work to decrease lung fibrosis and inflammation by focusing on various signaling pathways linked to fibrosis. As per the American Lung Association, a US-based lung association, in December 2022, the number of affected individuals in the United States stood around 207,000, with approximately 58,000 fresh cases of idiopathic pulmonary fibrosis identified annually, predominantly in men and individuals over 50 years old. Thus, an uptick in fibrotic diseases contributes to the expansion of the idiopathic pulmonary fibrosis market.

Which Segmentation Categories Are Highlighted In The Idiopathic Pulmonary Fibrosis Market Analysis?

The idiopathic pulmonary fibrosismarket covered in this report is segmented –

1) By Drug Type: Nintedanib; Pirfenidone; Other Drug Types

2) By Mode Of Action: Antifibrotic Agents; Tyrosine Kinase Inhibitors; Other Modes Of Action

3) By Route Of Administration: Oral; Parenteral

4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Providers

5) By End Users: Hospitals And Clinics; Other End Users

Subsegments:

1) By Nintedanib: Indications; Dosage Forms; Administration Routes

2) By Pirfenidone: Indications; Dosage Forms; Administration Routes

3) By Other Drug Types: Specific Agents Or Classes; Emerging Therapies; Combination Therapies

Which Trends Are Likely To Redefine Growth Paths In The Idiopathic Pulmonary Fibrosis Market?

A key trend emerging in the idiopathic pulmonary fibrosis market is product innovation. To secure their market positions and gain a competitive edge, major companies are focusing on developing innovative products. Sandoz, a Swiss manufacturer of generic and biosimilar medicines, for example, initiated the launch of a generic pirfenidone version in May 2022. This is the first AB-rated equivalent to Genentech’s Esbriet, primarily targeting the treatment of idiopathic pulmonary fibrosis (IPF) in patients. This prescription medication, taken orally, has now become available for patients via specialty pharmacies, and under a USD 0 co-pay program, eligible patients can avail its benefits.

Who Are The Dominant Players In The Idiopathic Pulmonary Fibrosis Market Today?

Major companies operating in the idiopathic pulmonary fibrosis market include F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Gilead Sciences Inc., Toray Industries Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Sun Pharmaceutical Industries Limited, Shionogi and Co. Ltd., Cipla Inc., Zydus Lifesciences Ltd., Chong Kun Dang Pharmaceutical Corp., Kyorin Pharmaceutical Co. Ltd., Galapagos NV, Veracyte Inc., Genentech Inc., FibroGen Inc., GNI Group Ltd., Pliant Therapeutics Inc., Pulmatrix Inc., Galimedix Therapeutics Inc., Avalyn Pharma Inc., MediciNova Inc., Liminal BioSciences Inc., Beijing Continent Pharmaceuticals Company, Galecto Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report

Which Regional Markets Are Emerging As Key Hubs For The Idiopathic Pulmonary Fibrosis Market?

North America was the largest region in the idiopathic pulmonary fibrosis market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the idiopathic pulmonary fibrosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=12579&type=smp

Browse Through More Reports Similar to the Global Idiopathic Pulmonary Fibrosis Market 2025, By The Business Research Company

Pulmonary Arterial Hypertension Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pulmonary-arterial-hypertension-global-market-report

Overactive Bladder Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/overactive-bladder-treatment-global-market-report

Constipation Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/constipation-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model